<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228134</url>
  </required_header>
  <id_info>
    <org_study_id>2017LCSY347</org_study_id>
    <nct_id>NCT03228134</nct_id>
  </id_info>
  <brief_title>Clinical Study on Treatment of Chronic Persistent Bronchial Asthma</brief_title>
  <official_title>Clinical Study on Treatment of Chronic Persistent Bronchial Asthma With Integrated Traditional Chinese and Western Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators aimed to evaluate the clinical efficacy of integrated traditional Chinese and
      Western medicine in the treatment of asthma, and to further optimize the prescription of
      Chinese medicine treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of asthma in China is high and the rate of control is low. Traditional Chinese
      medicine has a long history of treating asthma, and has a good clinical curative effect.The
      purpose of this study is to evaluate the clinical efficacy of traditional Chinese medicine in
      the treatment of asthma, and to further optimize the prescription of Chinese medicine
      treatment.

      In this study, investigators recruited chronic persistent asthma participants, and gave the
      corresponding western medicine background treatment and traditional Chinese medicine
      treatment program for 28 days.Participants will undergo a physical examination, lung
      function, blood and sputum collection.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All treatment group received traditional chinese medicine plus a standard anti-asthma treatment on study entry, and the control group received placebo and standard anti-asthma treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Double-blind trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma control rate change</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Measured the change from Baseline of asthma control rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung function(FEV1, PEF)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured routine pulmonary ventilation function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FeNO</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The fractional concentration of exhaled nitric oxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood routine examination</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Hematological routine examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function test</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Simple liver function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels of induced sputum</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Measured cytokine levels of induced sputum supernatant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function test</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Simple kidney function test</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>Hanxiao treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hanxiao control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule placebo oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xuxiao treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xuxiao control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule placebo oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ke Chuan Liu Wei Granule</intervention_name>
    <description>Traditional Chinese Medicine</description>
    <arm_group_label>Hanxiao treatment group</arm_group_label>
    <other_name>KCLW Granule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yang He Ping Chuan Granule</intervention_name>
    <description>Traditional Chinese Medicine</description>
    <arm_group_label>Xuxiao treatment group</arm_group_label>
    <other_name>YHPC Granule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ke Chuan Liu Wei Granule placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Hanxiao control group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Yang He Ping Chuan Granule placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Xuxiao control group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient diagnosed with chronic persistent asthma

          -  Patients had positive bronchodilator reversibility test or positive bronchial
             challenge test or more than 50 parts per billion of FENO before

          -  Conform to the predetermined 2 TCM Syndrome Types

          -  Patients who have given written informed consent

        Exclusion Criteria:

          -  Smoking and continuous exposure to hazardous environment

          -  With fever, or severity of intermittent state, high degree of sustained, or with
             respiratory failure, etc.

          -  Pulmonary emphysema, chronic obstructive pulmonary disease, pulmonary emphysema,
             pulmonary heart disease, pneumonia, lung cancer and other lung diseases

          -  Patients who are allergic to therapeutic medicine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huiyong Zhang, Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>tcmdoctorzhang@163.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zifeng Ma, Doctor</last_name>
    <phone>+8621-64385700</phone>
    <phone_ext>1307</phone_ext>
    <email>mzf05@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenghui Lu, PHD</last_name>
    <phone>+8621-64385700</phone>
    <phone_ext>1307</phone_ext>
    <email>tcmdoctorlu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fenglin Street Community Health Service Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangjian Street Community Health Service Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianping Street Community Health Service Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longhua Hospital Affiliated Shanghai University of TCM</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fengxian District Hospital of TCM</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201400</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatmentï¼› bronchial asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

